Back to Depression And Anxiety
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00599911

NCT00599911
Completed Phase 2 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You have been experiencing a major depressive episode that has lasted at least 3 months
  • Your depression is moderate to severe in intensity

Who may not be able to join:

  • You currently have a primary mental health diagnosis other than major depressive disorder (confirm with trial site)
  • You have a current or past history of manic or hypomanic episodes, schizophrenia, any psychotic disorder, depression with psychotic features, intellectual disability, or a mental health condition caused by a medical illness
  • Your depression has not responded to two separate courses of antidepressant medication, each lasting at least 6 weeks
  • You have had electroconvulsive therapy (ECT, sometimes called "shock therapy") within the 6 months before the study begins
  • You are currently receiving formal talking therapy (such as cognitive behavioural therapy) or plan to start such therapy during the study
  • You have a significant unstable physical health condition, such as serious liver, kidney, heart, lung, digestive, hormonal, neurological, infectious, cancer-related, or metabolic problems (confirm with trial site)
  • You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
H. Lundbeck A/S
Registry
clinicaltrials_gov
Start date
1 October 2007
Est. completion
1 March 2009

Where this trial is recruiting

🇦🇺 Australia 🇦🇹 Austria 🇧🇪 Belgium 🇨🇦 Canada 🇨🇿 Czechia 🇫🇮 Finland 🇫🇷 France 🇮🇳 India 🇱🇹 Lithuania 🇲🇾 Malaysia 🇳🇴 Norway 🇵🇭 Philippines 🇷🇺 Russia 🇷🇸 Serbia 🇰🇷 South Korea 🇸🇪 Sweden 🇺🇦 Ukraine

5 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

The difference in change from baseline to end of treatment on the Montgomery-Åsberg Depression Rating Scale total score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov